Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...

Osteoarthritis of the knee is a common and often painful condition affecting millions worldwide, especially older adults. As weight loss medications like Ozempic continue to gain traction for their ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

A recent poll found that about 15.5 million Americans have used injectable diabetes medicines like Ozempic and Wegovy to lose ...

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...